Mr. Hoang brings over twenty years of investment banking, venture capital, immuno-oncology and public company executive management experience to TapImmune, serving most recently as Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals. Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. Before joining MD Anderson, Mr. Hoang was a senior investment banker, most recently as Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group. He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.
Dr. Wilson brings an extensive background of success in corporate management and product development with tenures in both major multinational pharmaceutical companies and start-up pharmaceutical/biotech organizations. Dr. Wilson’s former positions include Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and President and co-founder of Auriga Pharmaceuticals. As Executive Vice President of R&D at Tacora Corporation he was responsible for merging the Company with Access Pharmaceuticals. He is a recognized leader in the development of drug delivery systems. Dr. Wilson has a Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York. He has been on the Board of TapImmune for 12 years.
Dr. Kenney currently serves as President of ClinReg Biologics, LLC. Prior to this role, Dr. Kenney served as Principal Medical Advisor and Chief Medical Officer of Immune Design Corp, where he established and led the clinical development of the company’s cancer prime-boost immunotherapeutics and vaccines. Previously, Dr. Kenney served as Chief Medical Officer of Crucell Holland, BV, where he directed clinical development of a broad platform of vaccines. He also served as Senior Vice President, Clinical Development for Vical Incorporated, where he led the clinical development of DNA vaccines. Dr. Kenney held key positions in vaccine development at GSK Biologicals from 2005 to 2009, most recently as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. He earned his M.D. degree at Harvard Medical School, completed his residency in Internal Medicine at Duke University Medical Center.
Mr. Loiacono has more than 25 years of financial management experience. At his previous company, FCTI, Inc., Michael was responsible for the company’s strategic development to include new products and services, new market penetration and maximizing gross and net revenues. In 2013, FCTI, Inc. acquired Global Axcess Corp, a publicly-traded company, where Michael served as CFO since 2006. At Global Axcess, Michael oversaw the overall financial strategy of the company, including capital raises, mergers & acquisitions, corporate finance, treasury, financial planning and analysis, accounting, investor relations, external auditing and was responsible for Global Axcess’ corporate strategy function. In 2009, Michael was named a Jacksonville, Florida Ultimate CFO of the year. Prior to FCTI/Global Axcess, Michael held various positions of increasing responsibility in finance management through several private and publicly-traded organizations.
Dr. Florkiewicz has experience in both academic and biotechnology environments. Most recently he conducted research on human embryonic stem cell-based therapies at the University of Washington. He was the Director of Cellular and Molecular Biology and co-founder of Ciblex Corporation, a spin-out from his laboratory at the Scripps Institute, San Diego. He was a patent agent at Seed Intellectual Law Group in Seattle and at ID Biomedical, where he managed the company’s intellectual property portfolio prior to and through its acquisition by GlaxoSmithKline. He has a Ph.D. in Molecular and Development Biology from the University of Arizona (focusing on the molecular biology of various RNA viruses) and was a postdoctoral fellow at the Salk Institute (focusing on the intracellular trafficking of proteins encoded by vesicular stomatitis virus). As a Research Scientist at Synergen, Inc., he helped establish the viral vector and animal cell expression group, and also discovered novel molecular mechanisms modulating FGF2 gene expression.
Elizabeth has almost 20 years of corporate administrative experience. Prior to TapImmune, Inc., she worked for System Designs, Inc. (SDI) as the office manager for eight years. SDI offered a complete medical electronic claims submission and management software. With over 1,500 customers all over the US, including Highmark, National Government Services, Cahaba, WPS, HP Services, Palmetto, BCBS, and Novitas. SDI was recently acquired by The ABILITY Network. Over the past 20 years, Elizabeth has worked in Human Resources for a large logistics company, a data analyst for a large MRO company that was recently acquired by Home Depot.
Sherry Grisewood, CFA, has accumulated over 30 years of securities industry experience in investment banking transaction, advisory and research-related capacities. She has participated in over 70 transaction and collaboration-related projects for North American, European and PacRim life science companies developing nucleic acid and regenerative medicine-based therapeutics, immunotherapeutics, orthopedics and therapeutic device technologies. Early in her career, Sherry published equity derivatives and market trading strategies and held positions at EF Hutton and Donaldson, Lufkin & Jenrette. Sherry is currently Managing Partner, Life Science Research of a leading life sciences specialty investment bank, having spent 15 years as an investment banker before returning to research in 2015. She is a co-founder of and holds Board seats for two medical device companies. Sherry earned a BSc. degree (Highest Honors) in Life Science from Ramapo College of New Jersey, is a member of the Am. Soc. of Gene & Cell Therapy, the Tissue Engineering and Regen. Medicine Soc. International, Soc. of Biomaterials, and the CFA Institute in addition to holding seven FINRA licenses.
Mr. Reddish has over 30 years of product development experience in the biotechnology industry, largely focused on vaccine development. He has over 50 publications in the field of immunology, vaccines and cancer immunotherapy. Mr. Reddish was VP of Vaccine development for ID Biomedical before it’s acquisition by GSK. He was previously VP of Development for TapImmune and a member of the Scientific Advisory Board and the Board of Directors. Since 2013 he has been VP of operations for Metrodora Inc a privately held biotech working in immunologic therapies of IBD/Crohn’s disease.
David, a Pharmacist by profession, founded Pharmafor ltd, a company providing specialist assistance to small and emerging enterprises in the medical technology sector. Having successfully been responsible for and involved in several spin-outs and start-ups he now focuses this knowledge and experience into assisting a portfolio of start-ups and growth companies. David is also CEO to one such company, London Pharma, a company re-purposing known molecules to new or improved uses. It has completed a phase III treatment for severe malaria in children and has embarked upon a Phase II treatment for cancers. Prior to this he has held a number of director, executive officer and general management posts in both small and major multinational companies including GSK plc, Abbott inc (now Abbvie inc), Amersham plc (now GEMS), Life Technologies inc, OSI inc (now Astellas), Bilcare and Surface Therapeutics. These have spanned the full range of activities ranging from discovery, through manufacturing to sale of pharmaceutical products, diagnostics and devices. He is a non-executive director of OBN Ltd, a highly successful trade association for SME enterprises in the Life Sciences sector.
Frederick (Rick) is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues. Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.
Mr. Silverman joined the Board in November 2016. Mr. Silverman is currently and has been the Co–founder and Managing Member of Parkfield Funding LLC, an investment and consulting firm, since May 15, 2013. Mr. Silverman was a former Principal and Managing Partner of Iroquois Capital Management, LLC (“Iroquois”), where he served as Co–Chief Investment Officer of Iroquois from 2003 until August 1, 2016. From 2000 to 2003, Mr. Silverman served as Co–Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to the President of the United States. Mr. Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr. Silverman has served on the boards of directors of Neurotrope, Inc., MGT Capital Investments Inc., National Holdings Corporation, Alanco Technologies Inc., Protagenic Therapeutics, Inc. and WPCS International Incorporated. Mr. Silverman brings to our Board extensive public company board experience, and financial and investment experience, including with pre-revenue biotechnology companies.
Scientific Advisory Board
Dr. Allison is a Co-Founder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of T cell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the T cell antigen receptor protein. His research led to the clinical development of ipilimumab (Yervoy®), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was Director of the Ludwig Center for Cancer Immunotherapy and Chair of the immunology program at the Memorial Sloan-Kettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial Sloan-Kettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as President of the American Association of Immunologists. He has received worldwide recognition for his contributions, including, the Lasker Clinical Medical Research Award, the Canada Gairdner International Award, the Szent-Györgyi Prize for Progress in Cancer Research and the Breakthrough Prize in Life Sciences for Innovative Cancer Immunology Research. Dr. Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.
Dr. Brenner is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics. He is also a member of the Texas Children’s Cancer and Hematology Center, the Stem Cell and Regenerative Medicine Center, and the Dan L. Duncan Comprehensive Cancer Center at Baylor. Over the past 30 years, Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and International Society for Cell Therapy. Dr. Brenner has earned widespread recognition for his scientific achievements and leadership in the field, including the ASGCT Outstanding Achievement Award, Human Gene Therapy’s Pioneer Award, and the American Society of Hematology Mentor Award. Most recently Dr. Brenner has been elected to the prestigious National Academy of Medicine for his contributions. He obtained his BA and medical degrees as well as his Ph.D. from the University of Cambridge in the UK where he became a fellow of the Royal College of Pathologists and the Royal College of Physicians. Dr. Brenner is a co-founder of ViraCyte, LLC.
Dr. Rooney is a Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, and Immunology and Director of Translational Research Laboratories at the Center for Cell and Gene Therapy at Baylor College of Medicine. Dr. Rooney is renowned virologist and immunologist who, in collaboration with Drs. Heslop and Brenner, was the first to demonstrate that antigen-specific T cells generated in the laboratory could prevent and cure viral-associated malignancies in humans following hematopoietic stem cell transplantation. She has been key in extending this successful strategy to develop and clinically test a range of post-transplant viral infections and diseases. Dr. Rooney serves on the Editorial Boards for several scientific journals, including Molecular Therapy, Cytotherapy, Molecular and Cellular Therapies. Dr. Rooney holds a Ph.D. in immunology from the University of Cambridge and a B.Sc. in Genetics from the University of East Anglia in England. Dr. Rooney is a co-founder of ViraCyte, LLC.
A leading cancer immunotherapy translational scientist, Dr. Sharma is a Co-Founder of Jounce Therapeutics and currently serves as scientific director and professor in the departments of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting anti-tumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including a Department of Defense (DOD) Idea Development Award (2010), a Cancer Prevention Research Institute of Texas (CPRIT) Individual Investigator Award (2011), a National Institute of Health (NIH/NCI) R01 Award (2012) and an AACR-CRI-SU2C Immunotherapy dream team grant (2013). Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She also holds a B.A. in biology and an M.A. in biotechnology from Boston University.
Dr. Heslop is Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital. She is the Dan L. Duncan Chair and the Associate Director of Clinical Research at the Dan L. Duncan Cancer Center. Trained as a physician-scientist, Dr. Heslop is a prominent figure engaged in translational research focusing on adoptive T cell immunotherapy to improve hematopoietic stem cell transplantation and cancer therapy. In collaboration with Drs. Brenner and Rooney, her initial studies were the first to demonstrate the feasibility of using EBV-specific T cells to prevent and treat EBV-associated malignancy in stem cell transplant patients, thereby validating the safety and efficacy of adoptive T cell transfer as a therapeutic modality. Dr. Heslop was a Doris Duke Distinguished Clinical Research Scientist and serves as the current President elect of the American Society for Gene and Cell Therapy (ASGCT) and a past President of the Foundation for Accreditation of Cell Therapy (FACT) and the American Society of Blood and Marrow Transplantation. She received her M.B.ChB, M.D. and D.Sc. (Hon) in Hematology from the University of Otago in New Zealand. Dr. Heslop is a co-founder of ViraCyte, LLC.